Strides Pharma says could take 3-4 qtrs for normalcy of US business hit price erosion

The company on Wednesday reported a net loss of Rs 168 crore in Q2FY22. In the H1FY22, Strides accumulated a net loss of Rs 376.6. Revenues declined 9% YoY to Rs 736 crore. US business alone contributed more than one-third of revenues at Rs 250.2 crore ($34 million)in Q2FY22, down 38% YoY. At its peak, Stride's US business was hitting $58 million on a quarterly basis.

via Economictimes